Galectin Therapeutics is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. The Company’s drug candidates are based on unique carbohydrate technology to target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. The Company is pursuing a clear development pathway to clinical enhancement and commercialization for lead compounds in liver fibrosis and cancer immunotherapy. Galectin Therapeutics is headquartered in Norcross, GA. It is a publicly traded company and is listed on the NASDAQ Global Market under the symbol GALT.